Study of 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma

Alberta Health services

Status and phase: Completed; Phase 2

Conditions: Colorectal Adenocarcinoma; Liver Metastases

Treatments: Drug: perioperative chemotherapy

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00168155

CPTAIV-0020-357

Details and patient eligibility

About

When colon or rectal cancer has spread to the liver, the cancer in the liver can sometimes be removed surgically. However, the cancer has a chance or reoccurring in the liver or elsewhere in the body. This study will determine if giving chemotherapy treatment before the surgery can reduce the chances that the cancer will come back.

Full description

When colon or rectal cancer has spread to the liver, the cancer in the liver can sometimes be removed surgically. However, the cancer has a chance or reoccurring in the liver or elsewhere in the body. This study will determine if giving chemotherapy treatment before the surgery can reduce the chances that the cancer will come back.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• stage IV colorectal cancer isolated to the liver
• one measurable lesion
• metastases are completely resectable or amenable to ablation
• Karnofsky >70
• Adequate bone marrow function
• adequate hepatic function
• adequate renal function
• informed consent

Exclusion criteria

• primary tumor not controlled by locoregional treatments
• bilateral portal vein and/or hepatic artery involvement
• previous chemotherapy directed at treatment of metastatic colorectal cancer
• underlying acute or chronic liver disease
• Gilbert's disease
• patients receiving phenytoin or phenobarbital prophylaxis
• presence of any concurrent medical or psychiatric condition that serves as a contraindication to surgery or chemotherapy
• pregnancy
• malignancy other than basal cell or squamous cell carcinoma of the skin within the preceding 5 years
• use of another investigational medication concurrently or within 4 months of enrollment

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)